New agents for the treatment of acute myeloid leukemia

Best Practice & Research. Clinical Haematology
Martin S Tallman

Abstract

The heterogeneity of acute myeloid leukemia (AML) has been established by many new insights into the diagnosis, pathogenesis, clinical manifestations, treatment, and prognosis of patients with AML. Morphology remains the foundation for the diagnosis. However, additional diagnostic studies, including immunophenotyping, cytogenetic evaluation, and molecular genetic studies, are necessary to develop treatments because specific subtypes of AML can now be approached with targeted therapy. Acute promyelocytic leukemia (APL), defined by a single molecular abnormality, is now treated with specific targeted therapy, all-trans retinoic acid (ATRA), and this subtype of AML is now highly curable. Currently, a number of agents have been explored in AML, including anti-CD33 antibodies and immunoconjugate drugs, inhibitors of multidrug resistance proteins, farnesyl transferase inhibitors, tyrosine kinase inhibitors, anti-Bcl-2 transcription agents, and inhibitors of mammalian target of rapamycin (mTOR). New alkylating agents, and purine analogs such as Cloretazine and clofarabine, affect DNA and ribonucleoside reductases, respectively. These agents have shown promise in small studies. Large phase III studies will address whether these are eff...Continue Reading

References

Mar 17, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter L GreenbergJacob M Rowe
May 8, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Francis GilesHagop Kantarjian
Nov 20, 2004·Blood·Christian RécherBernard Payrastre
Apr 13, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guido MarcucciJohn C Byrd
May 5, 2005·Blood·Martin S TallmanJacob M Rowe

❮ Previous
Next ❯

Citations

Oct 7, 2008·Oncogene·N Nausch, A Cerwenka
Sep 2, 2010·Current Opinion in Oncology·Ulrike BacherTorsten Haferlach
Jan 27, 2007·Current Opinion in Hematology·Torsten HaferlachSusanne Schnittger
Feb 11, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Bella S GuerrouahenSeth J Corey
May 12, 2007·Expert Review of Anticancer Therapy·Nina AnensenBjørn T Gjertsen
Aug 25, 2009·Best Practice & Research. Clinical Haematology·Ulrike BacherTorsten Haferlach
Jul 7, 2009·Biochemical Pharmacology·Anna ZhenchukFreidoun Albertioni
Aug 12, 2008·Seminars in Oncology·Wai-In Chan, Brian J P Huntly
Apr 7, 2009·British Journal of Haematology·Ulrike BacherTorsten Haferlach
Jan 31, 2007·Journal of Digestive Diseases·Jin Ping ZhangJian Sheng Li
Aug 5, 2014·Experimental Cell Research·Mariarita PerriMaureen A Kane
Mar 18, 2015·Bioorganic & Medicinal Chemistry·Kayla M BorlandVladislav A Litosh
Jun 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guido MarcucciUNKNOWN Cancer and Leukemia Group B Study
May 5, 2010·Oncology Nursing Forum·Barbara B Rogers
Aug 5, 2014·American Journal of Hematology·Melhem SolhCelalettin Ustun
Jul 26, 2014·Journal of Intellectual Disabilities : JOID·Gro Aasen, Terje Naerland
Mar 27, 2007·Advances in Enzyme Regulation·James A McCubreyAlberto M Martelli

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Related Papers

Current Treatment Options in Oncology
Margaret von Mehren
Current Opinion in Oncology
Michael E Williams, John J Densmore
Current Oncology Reports
Santosh KesariPatrick Y Wen
Best Practice & Research. Clinical Endocrinology & Metabolism
James C Yao
© 2021 Meta ULC. All rights reserved